(EW) Edwards Lifesciences - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US28176E1082
Stock: Heart Valves, Catheters, Surgical Devices, Cardiovascular Care
Total Rating 45
Risk 83
Buy Signal -0.38
| Risk 5d forecast | |
|---|---|
| Volatility | 27.3% |
| Relative Tail Risk | -14.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.49 |
| Alpha | 0.94 |
| Character TTM | |
|---|---|
| Beta | 0.559 |
| Beta Downside | 0.631 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.53% |
| CAGR/Max DD | 0.09 |
EPS (Earnings per Share)
Revenue
Description: EW Edwards Lifesciences March 04, 2026
Edwards Lifesciences Corporation (EW) develops products for advanced cardiovascular diseases globally. The company specializes in transcatheter and surgical heart valve therapies. This includes transcatheter aortic valve replacement (TAVR) systems, a key growth area in medical devices, and products for mitral and tricuspid valve diseases.
Their product portfolio features the Edwards SAPIEN family for TAVR, PASCAL and EVOQUE for valve repair/replacement, and INSPIRIS and KONECT RESILIA for surgical applications. The medical device sector is characterized by high R&D investment and regulatory hurdles. Products are distributed via direct sales and independent distributors.
Further analysis on ValueRay can provide deeper insights into EWs market position and financial performance.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 1.07b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.45 > 1.0 |
| NWC/Revenue: 81.17% < 20% (prev 87.61%; Δ -6.44% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.60b > Net Income 1.07b |
| Net Debt (-2.23b) to EBITDA (1.39b): -1.60 < 3 |
| Current Ratio: 3.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (581.8m) vs 12m ago -1.47% < -2% |
| Gross Margin: 78.08% > 18% (prev 0.79%; Δ 7729 % > 0.5%) |
| Asset Turnover: 45.36% > 50% (prev 41.79%; Δ 3.57% > 0%) |
| Interest Coverage Ratio: -32.41 > 6 (EBITDA TTM 1.39b / Interest Expense TTM -38.1m) |
Altman Z'' 10.00
| A: 0.36 (Total Current Assets 6.74b - Total Current Liabilities 1.81b) / Total Assets 13.70b |
| B: 1.04 (Retained Earnings 14.24b / Total Assets 13.70b) |
| C: 0.09 (EBIT TTM 1.23b / Avg Total Assets 13.38b) |
| D: 4.36 (Book Value of Equity 14.66b / Total Liabilities 3.36b) |
| Altman-Z'' Score: 10.95 = AAA |
Beneish M -2.89
| DSRI: 1.13 (Receivables 912.1m/727.4m, Revenue 6.07b/5.46b) |
| GMI: 1.01 (GM 78.08% / 79.07%) |
| AQI: 0.96 (AQ_t 0.37 / AQ_t-1 0.38) |
| SGI: 1.11 (Revenue 6.07b / 5.46b) |
| TATA: -0.04 (NI 1.07b - CFO 1.60b) / TA 13.70b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of EW shares?
As of March 07, 2026, the stock is trading at USD 81.64 with a total of 4,351,140 shares traded.
Over the past week, the price has changed by -5.59%, over one month by +3.72%, over three months by -3.18% and over the past year by +13.70%.
Over the past week, the price has changed by -5.59%, over one month by +3.72%, over three months by -3.18% and over the past year by +13.70%.
Is EW a buy, sell or hold?
Edwards Lifesciences has received a consensus analysts rating of 3.69.
Therefor, it is recommend to hold EW.
- StrongBuy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the EW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.5 | 18.2% |
| Analysts Target Price | 96.5 | 18.2% |
EW Fundamental Data Overview March 07, 2026
P/E Trailing = 46.3481
P/E Forward = 29.6736
P/S = 8.0301
P/B = 4.846
P/EG = 3.3177
Revenue TTM = 6.07b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 1.39b USD
Long Term Debt = 598.2m USD (from longTermDebt, two quarters ago)
Short Term Debt = 24.5m USD (from shortTermDebt, last quarter)
Debt = 705.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.23b USD (from netDebt column, last quarter)
Enterprise Value = 45.20b USD (48.72b + Debt 705.4m - CCE 4.23b)
Interest Coverage Ratio = -32.41 (Ebit TTM 1.23b / Interest Expense TTM -38.1m)
EV/FCF = 33.86x (Enterprise Value 45.20b / FCF TTM 1.33b)
FCF Yield = 2.95% (FCF TTM 1.33b / Enterprise Value 45.20b)
FCF Margin = 22.00% (FCF TTM 1.33b / Revenue TTM 6.07b)
Net Margin = 17.64% (Net Income TTM 1.07b / Revenue TTM 6.07b)
Gross Margin = 78.08% ((Revenue TTM 6.07b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 78.30% (prev 77.77%)
Tobins Q-Ratio = 3.30 (Enterprise Value 45.20b / Total Assets 13.70b)
Interest Expense / Debt = 3.94% (Interest Expense 27.8m / Debt 705.4m)
Taxrate = 28.98% (26.2m / 90.4m)
NOPAT = 876.9m (EBIT 1.23b * (1 - 28.98%))
Current Ratio = 3.72 (Total Current Assets 6.74b / Total Current Liabilities 1.81b)
Debt / Equity = 0.07 (Debt 705.4m / totalStockholderEquity, last quarter 10.34b)
Debt / EBITDA = -1.60 (Net Debt -2.23b / EBITDA 1.39b)
Debt / FCF = -1.67 (Net Debt -2.23b / FCF TTM 1.33b)
Total Stockholder Equity = 10.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.0% (Net Income 1.07b / Total Assets 13.70b)
RoE = 10.39% (Net Income TTM 1.07b / Total Stockholder Equity 10.30b)
RoCE = 11.33% (EBIT 1.23b / Capital Employed (Equity 10.30b + L.T.Debt 598.2m))
RoIC = 8.05% (NOPAT 876.9m / Invested Capital 10.89b)
WACC = 7.90% (E(48.72b)/V(49.43b) * Re(7.97%) + D(705.4m)/V(49.43b) * Rd(3.94%) * (1-Tc(0.29)))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.09%
[DCF] Terminal Value 75.06% ; FCFF base≈1.08b ; Y1≈874.6m ; Y5≈609.9m
[DCF] Fair Price = 23.55 (EV 11.44b - Net Debt -2.23b = Equity 13.68b / Shares 580.8m; r=7.90% [WACC]; 5y FCF grow -22.61% → 2.90% )
EPS Correlation: 20.22 | EPS CAGR: -0.90% | SUE: -1.59 | # QB: 0
Revenue Correlation: 62.83 | Revenue CAGR: 4.28% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.75 | Chg7d=+0.001 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=25
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.004 | Chg30d=+0.019 | Revisions Net=+5 | Growth EPS=+15.5% | Growth Revenue=+9.9%
EPS next Year (2027-12-31): EPS=3.31 | Chg7d=+0.005 | Chg30d=+0.075 | Revisions Net=+21 | Growth EPS=+11.8% | Growth Revenue=+9.8%
[Analyst] Revisions Ratio: +0.14 (8 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 8.0% - Earnings Yield 2.2%)
[Growth] Growth Spread = +4.0% (Analyst 9.8% - Implied 5.8%)
P/E Forward = 29.6736
P/S = 8.0301
P/B = 4.846
P/EG = 3.3177
Revenue TTM = 6.07b USD
EBIT TTM = 1.23b USD
EBITDA TTM = 1.39b USD
Long Term Debt = 598.2m USD (from longTermDebt, two quarters ago)
Short Term Debt = 24.5m USD (from shortTermDebt, last quarter)
Debt = 705.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.23b USD (from netDebt column, last quarter)
Enterprise Value = 45.20b USD (48.72b + Debt 705.4m - CCE 4.23b)
Interest Coverage Ratio = -32.41 (Ebit TTM 1.23b / Interest Expense TTM -38.1m)
EV/FCF = 33.86x (Enterprise Value 45.20b / FCF TTM 1.33b)
FCF Yield = 2.95% (FCF TTM 1.33b / Enterprise Value 45.20b)
FCF Margin = 22.00% (FCF TTM 1.33b / Revenue TTM 6.07b)
Net Margin = 17.64% (Net Income TTM 1.07b / Revenue TTM 6.07b)
Gross Margin = 78.08% ((Revenue TTM 6.07b - Cost of Revenue TTM 1.33b) / Revenue TTM)
Gross Margin QoQ = 78.30% (prev 77.77%)
Tobins Q-Ratio = 3.30 (Enterprise Value 45.20b / Total Assets 13.70b)
Interest Expense / Debt = 3.94% (Interest Expense 27.8m / Debt 705.4m)
Taxrate = 28.98% (26.2m / 90.4m)
NOPAT = 876.9m (EBIT 1.23b * (1 - 28.98%))
Current Ratio = 3.72 (Total Current Assets 6.74b / Total Current Liabilities 1.81b)
Debt / Equity = 0.07 (Debt 705.4m / totalStockholderEquity, last quarter 10.34b)
Debt / EBITDA = -1.60 (Net Debt -2.23b / EBITDA 1.39b)
Debt / FCF = -1.67 (Net Debt -2.23b / FCF TTM 1.33b)
Total Stockholder Equity = 10.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.0% (Net Income 1.07b / Total Assets 13.70b)
RoE = 10.39% (Net Income TTM 1.07b / Total Stockholder Equity 10.30b)
RoCE = 11.33% (EBIT 1.23b / Capital Employed (Equity 10.30b + L.T.Debt 598.2m))
RoIC = 8.05% (NOPAT 876.9m / Invested Capital 10.89b)
WACC = 7.90% (E(48.72b)/V(49.43b) * Re(7.97%) + D(705.4m)/V(49.43b) * Rd(3.94%) * (1-Tc(0.29)))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.09%
[DCF] Terminal Value 75.06% ; FCFF base≈1.08b ; Y1≈874.6m ; Y5≈609.9m
[DCF] Fair Price = 23.55 (EV 11.44b - Net Debt -2.23b = Equity 13.68b / Shares 580.8m; r=7.90% [WACC]; 5y FCF grow -22.61% → 2.90% )
EPS Correlation: 20.22 | EPS CAGR: -0.90% | SUE: -1.59 | # QB: 0
Revenue Correlation: 62.83 | Revenue CAGR: 4.28% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.75 | Chg7d=+0.001 | Chg30d=+0.006 | Revisions Net=+2 | Analysts=25
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.004 | Chg30d=+0.019 | Revisions Net=+5 | Growth EPS=+15.5% | Growth Revenue=+9.9%
EPS next Year (2027-12-31): EPS=3.31 | Chg7d=+0.005 | Chg30d=+0.075 | Revisions Net=+21 | Growth EPS=+11.8% | Growth Revenue=+9.8%
[Analyst] Revisions Ratio: +0.14 (8 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 8.0% - Earnings Yield 2.2%)
[Growth] Growth Spread = +4.0% (Analyst 9.8% - Implied 5.8%)